٥

AMENDMENTS TO THE CLAIMS

Please amend the claims as indicated below:

- 1-29 (Cancelled).
- 30. (Previously presented) The method of Claim 41, wherein R_a is $-OR_1$.
- 31. (Previously presented) The method of Claim 41, wherein R_a is -OCOR₁.
- 32. (Previously presented) The method of Claim 41, wherein the neovascularization is ocular neovascularization.
- 33. (Previously presented) The method of Claim 30, wherein the neovascularization is ocular neovascularization.
- 34. (Previously presented) The method of Claim 31, wherein the neovascularization is ocular neovascularization.
- 35. (Previously presented) The method of Claim 41, wherein the compound is 2-methoxyestradiol.
- 36. (Previously presented) The method of Claim 30, wherein the compound is 2-methoxyestradiol.
- 37. (Previously presented) The method of Claim 31, wherein the compound is 2-methoxyestradiol.
- 38. (Previously presented) The method of Claim 41, wherein the neovascularization is ocular neovascularization and the compound is 2-methoxyestradiol.
- 39. (Previously presented) The method of Claim 30, wherein the neovascularization is ocular neovascularization and the compound is 2-methoxyestradiol.
- 40. (Previously presented) The method of Claim 31, wherein the neovascularization is ocular neovascularization and the compound is 2-methoxyestradiol.

41. (Currently amended) A method of inhibiting neovascularization in a mammal, comprising administering to the mammal a neovascularization-inhibiting amount of a compound of the formula:

wherein, Ra is -R₁, -OR₁, -OCOR₁, -SR₁, -F, -NHR₂, -Br, or -I and wherein, in each formula set forth above, each R₁ and R₂ independently is -H, or a substituted or unsubstituted alkyl, alkenyl or alkynyl group of up to 6 carbons; and

provided that Ra is not H.